HC Wainwright Forecasts Reduced Earnings for GH Research

GH Research PLC (NASDAQ:GHRS) – Equities researchers at HC Wainwright lowered their FY2025 earnings estimates for shares of GH Research in a report issued on Monday, March 2nd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.78) for the year, down from their previous forecast of ($0.76). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research’s Q4 2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($1.02) EPS.

Several other research analysts have also recently issued reports on GHRS. Canaccord Genuity Group increased their price target on GH Research from $35.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Royal Bank Of Canada upped their price objective on shares of GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Wolfe Research set a $39.00 target price on shares of GH Research in a research report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.75.

GH Research Price Performance

GHRS opened at $15.17 on Thursday. The stock’s 50 day moving average price is $15.38 and its 200 day moving average price is $14.21. The stock has a market cap of $789.30 million, a P/E ratio of -20.50 and a beta of 1.00. GH Research has a 12 month low of $7.98 and a 12 month high of $19.51.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.06.

Institutional Investors Weigh In On GH Research

Hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC boosted its stake in GH Research by 63.4% in the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after purchasing an additional 822 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in GH Research during the 4th quarter valued at $38,000. Osaic Holdings Inc. lifted its holdings in shares of GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of GH Research in the second quarter valued at $79,000. Finally, Virtus Investment Advisers LLC acquired a new stake in shares of GH Research in the second quarter worth $89,000. 56.90% of the stock is currently owned by institutional investors.

Key Headlines Impacting GH Research

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: Company business update: GHRS reported completion of the Phase 2b trial of GH001 in treatment‑resistant depression, presented the full dataset at ASCP and ECNP, and announced FDA clearance to begin U.S. clinical investigations (allowing U.S. enrollment). The update also showed cash, cash equivalents and marketable securities of $280.7M at year‑end — supportive for near‑term development funding. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly results beat: GHRS reported EPS of ($0.23) for the quarter, beating consensus ($0.29) — a modest operational beat that can be viewed as a short‑term positive. Press Release
• Positive Sentiment: Analyst support: HC Wainwright retains a Buy rating and a $70 price target; an article also notes a $70 price‑target raise reported by coverage outlets — this maintains a constructive longer‑term analyst stance. Price Target Raised to $70.00
• Neutral Sentiment: Short‑interest note: the published short‑interest snapshot shows effectively zero reported short position and a 0.0 days‑to‑cover figure — data appears noisy/insignificant and is not clearly informative for immediate directional pressure.
• Neutral Sentiment: Long‑range projection: HC Wainwright issued a FY2030 EPS forecast of $1.54 per share — a distant, model‑dependent projection that provides upside in scenarios where development and commercialization succeed but has limited near‑term impact. HC Wainwright estimates (MarketBeat)
• Negative Sentiment: Multi‑year estimate cuts: HC Wainwright cut EPS forecasts across Q4 2025 and FY2025–FY2028 (and adjusted FY2026–FY2027 materially lower), reflecting a more conservative near‑to‑mid term earnings outlook; these downward revisions are a primary near‑term negative catalyst for the stock. HC Wainwright estimates (MarketBeat)

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.